Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old experienced significant hair regrowth in six months using 0.5mg Dutasteride and 2.5mg Minoxidil daily, with no side effects. The results were impressive enough to be mistaken for a hair transplant.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

A 24-year-old shares six months of hair loss treatment progress using oral finasteride, oral minoxidil, derma-stamping with topical minoxidil, and keto shampoo. The user is pleased with the results and plans to continue for another six months before considering a hair transplant.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

GHK-CU is not considered as effective for hair loss as finasteride, minoxidil, or RU58841, with many users reporting minimal benefits. Some users experienced skin improvements, but its impact on hair is debated and often attributed to concurrent use of other treatments.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

The user is experiencing hair loss and is using oral treatments including 5mg minoxidil, 1.1mg finasteride, and 1mg biotin daily. They are considering adding dutasteride and possibly a hair system, while others suggest patience and additional treatments like microneedling.

The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.

The user has seen positive results after over six months using 0.05% topical finasteride, 5% minoxidil, 50mg/ml RU58841, weekly needling, and twice-weekly ketoconazole shampoo for hair loss. They express gratitude for the support from an online community and are open to questions about their treatment.

The user "natiggiz" shared their early progress in filling in bald patches using topical finasteride, minoxidil, RU58841, ketoconazole, and derma stamp. Other users commented on the great results and expressed jealousy.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conclusion of this conversation is that the user, NickkSpirit, had a successful hair transplant with 1500 grafts. They recommend leading a healthy lifestyle and mention using finasteride and minoxidil as treatments for hair loss.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

The user is pleased with increased hair density and thickness after six months of using topical minoxidil and finasteride. They plan to continue the treatment and consider adding dermarolling for potentially better results.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

A 26-year-old male shared his six-month results using oral dutasteride (0.5 mg/day) and oral minoxidil (3.5 mg/day), noting increased density but little change in the receding hairline. Users suggested dermarolling and adding topical minoxidil for better results, while OP reported no side effects from dutasteride.